Prevention of tumors of the large intestine by celecoxib in mice

In Vivo

Volumn 19, Issue 4, 2005, Pages 661-665

  Coles, Melissa ^a   Toth, Bela ^a  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

Author keywords

Cancer; Celecoxib; COX 2; Intestine; Prevention

Indexed keywords

1,2 DIMETHYLHYDRAZINE; CELEBREX C; CELECOXIB; CYCLOOXYGENASE 2 INHIBITOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CHEMOPROPHYLAXIS; COLON ADENOCARCINOMA; COLON POLYP; COLON TUMOR; CONTROLLED STUDY; DRUG DOSE REGIMEN; DRUG STRUCTURE; FEMALE; MEDICAL LITERATURE; MOUSE; NONHUMAN; PUBLICATION; RECTUM CARCINOMA; STATISTICAL SIGNIFICANCE; TUMOR VOLUME;

EID: 21344461944     PISSN: 0258851X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Penning TD, Talley JJ, Bertenshaw SR, Carter JS, Collins PW, Docter S, Graneto MJ, Lee LF, Malecha JW, Miyashiro JM, Rogers RS, Rogier DJ, Yu SS, Anderson GD, Burton EG, Cogburn JN, Gregory SA, Koboldt CM, Perkins WE, Seibert K, Veenhuizen AW, Zhang YY and Isakson PC: Synthesis and biological evaluation of the 1,5-diarylpyrazole class of cyclooxygenase-2 inhibitors: identification of 4-[5-(4-methylphenyl)-3-(trifluoromethyl) -1H-pyrazol-1yl]benzene-sulfonaminde (SC-58635, celecoxib). J Med Chem 40: 1347-1365, 1997.
2. Eberhart CE, Coffey RJ, Radhika A, Giardiello FM, Ferrenbach S and DuBois RN: Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas. Gastroenterology 107: 1183-1188, 1994.
3. Kargman SL, O'Neill GP, Vickers PJ, Evans JF, Mancini JA and Jothy S: Expression of prostaglandin G/H synthase-1 and -2 protein in human colon cancer. Cancer Res 55: 2556-2559, 1995.
4. Sano H, Kawahito Y, Wilder RL, Hashiramoto A, Mukai S, Asai K, Kimura S, Kato H, Kondo M and Hla T: Expression of cyclooxygenase-1 and -2 in human colorectal cancer. Cancer Res 55: 3785-3789, 1995.
5. DuBois RN, Radhika A, Reddy BS and Entingh AJ: Increased cyclooxygenase-2 levels in carcinogen-induced rat colonic tumors. Gastroenterology 110: 1259-1262, 1996.
6. Δ716 knockout mice by inhibition of cyclooxygenase 2 (COX-2). Cell 87: 803-809, 1996.
7. Tsujii M and DuBois RN: Alterations in cellular adhesion and apoptosis in epithelial cells overexpressing prostaglandin endoperoxide synthesis 2. Cell 83: 493-501, 1995.
8. Jacoby RF, Seibert K, Cole CE, Kelloff G and Lubet RA: The cyclooxygenase-2 inhibitor celecoxib is a potent preventive and therapeutic agent in the min mouse model of adenomatous polyposis. Cancer Res 60: 5040-5044, 2000.
9. Kawamori T, Rao CV, Seibert K and Reddy BS: Chemopreventive activity of celecoxib, a specific cyclooxygenase-2 inhibitor, against colon carcinogenesis. Cancer Res 58: 409-412, 1998.
10. Reddy BS, Hirose Y, Lubet R, Steele V, Kelloff G, Paulson S, Seibert K and Rao CV: Chemoprevention of colon cancer by specific cyclooxygenase-2 inhibitor, celecoxib, administered during different stages of carcinogenesis. Cancer Res 60: 293-297, 2000.
11. Brown WA, Skinner SA, Malcontenti-Wilson C, Misajon A, Dejong T, Vogiagis D and O'Brien PE: Non-steroidal anti-inflammatory drugs with different cyclooxygenase inhibitory profiles that prevent aberrant crypt foci formation but vary in acute gastrotoxicity in a rat model. J Gastroenterol Hepatol 15: 1386-1392, 2000.
12. Brown WA, Skinner SA, Malcontenti-Wilson C, Vogiagis D and O'Brien PE: Non-steriodal anti-inflammatory drugs with activity against either cyclooxygenase 1 or cyclooxygenase 2 inhibit colorectal cancer in a DMH rodent model by inducing apoptosis and inhibiting cell proliferation. Gut 48: 660-666, 2001.
13. Rao CV, Indranie C, Simi B, Manning PT, Connor JR and Reddy BS: Chemopreventive properties of a selective inducible nitric oxide synthase inhibitor in colon carcinogenesis, administered alone or in combination with celecoxib, a selective cyclooxygenase-2 inhibitor. Cancer Res 62: 165-170, 2002.
14. Steinbach G, Lynch PM, Phillips RKS, Wallace MH, Hawk E, Gordon G, Wakabayashi N, Saunders B, Shen Y, Fujimura T, Su L-K, Levin B, Godio L, Patterson S, Rodriguez-Bigas MA, Jester SL, King KL, Schumacher M, Abbruzzese J, DuBois RN, Hittelman WN, Zimmerman S, Sherman JW and Kelloff G: The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N Eng J Med 342: 1946-1952, 2000.
15. Rahme E, Barkun AN, Toubouti Y and Bardou M: The cyclooxygenase-2 selective inhibitors rofecoxib and celecoxib prevent colorectal neoplasia occurrence and recurrence. Gastroenterology 125: 404-412, 2003.
16. Phillips RKS, Wallace MH, Lynch PM, Hawk E, Gordon GB, Saunders BP, Wakabayashi N, Shen Y, Zimmerman S, Godio L, Rodrigues-Bigas M, Su L-K, Sherman J, Kelloff G, Levin B, Steinbach G and FAP Study Group: A randomized, double blind, placebo controlled study of celecoxib, a selective cyclooxygenase 2 inhibitor, on duodenal polyposis in familial adenomatous polyposis. Gut 50: 857-860, 2002.
17. Altman DG: Practical Statistics for Medical Research. Chapter 9: Comparing groups-continuous data. Chapman & Hall. New York, pp. 194-215, 1991.
18. Toth B, Malick L and Shimizu H: Production of intestinal and other tumors by 1,2-dimethylhydrazine dihydrochloride in mice. I. A light and transmission electron microscopic study of colonic neoplasms. Am J Pathol 84: 69-86, 1976.
19. Toth B, Magee PN and Shubik P: Carcinogenesis study with dimethylnitrosamine administered orally to adult and subcutaneously to newborn BALB/c mice. Cancer Res 24: 1712-1721, 1974.
20. Toth B and Shimizu H: 1-Carbamyl-2-phenylhydrazine tumorigenesis in Swiss mice. Morphology of lung adenomas. J Nad Cancer Inst 52: 241-251, 1974.
21. Toth B, Rappaport H and Shubik P: The influence of dose and age on the induction of malignant lymphomas and other tumors by 7,12-dimethylbenz(α)anthracene in Swiss mice. J Natl Cancer Inst 30: 723-741, 1963.
22. Fischer SM, Lo H-H, Gordon GB, Seibert & Kelloff G, Lubert RA and Conti CJ: Chemopreventive activity of celecoxib, a specific cyclooxygenase-2 inhibitor, and indomethacin against ultraviolet light-induced skin carcinogenesis. Mol Carcinog 25: 231-240, 1999.
23. Fischer SM, Conti CJ, Viner J, Aldaz CM and Lubet RA: Celecoxib and difluoromethylornithine in combination have strong therapeutic activity against UV-induced skin tumors in mice. Carcinogenesis 24: 945-952, 2003.
24. Grubbs CJ, Lubet RA, Koki AT, Leahy KM, Masferrer JL, Steele VE, Kelloff GJ, Hill DL and Seibert K: Celecoxib inhibits n-butyl-(4-hydroxybutyl)-nitrosamine-induced urinary bladder cancers in male B6D2F1 mice and female Fischer-334 rats. Cancer Res 60: 5599-5602, 2000.
25. Howe LR, Subbaramaiah K, Patel J, Masferrer J L, Deora A, Hudis C, Thaler HT, Muller WJ, Du B, Brown AMC and Dannenberg AJ: Celecoxib, a selective cyclooxygenase 2 inhibitor, protects against human epidermal growth factor receptor 2 (HER-2)/neu-induced breast cancer. Cancer Res 62: 5405-5407, 2002.
26. Gupta S, Adhami VM, Subbarayan M, MacLennan GT, Lewin JS, Hafeli UO, Fu P and Mukhtar H: Suppression of prostate carcinogenesis by dietary supplementation of celecoxib in transgenic adenocarcinomas of the mouse prostate model. Cancer Res 64: 3334-3343, 2004.
27. Harris RE, Alshafie GA, Abou-Issa H and Seibert K: Chemoprevention of breast cancer in rats by celecoxib, a cyclooxygenase 2 inhibitor. Cancer Res 60: 2101-2103, 2000.
28. Alshafie GA, Abou-Issa HM, Seibert K and Harris RE: Chemotherapeutic evaluation of celecoxib, a cyclooxygenase-2 inhibitor, in a rat mammary tumor model. Oncology Rep 7: 1377-1381, 2000.
29. Hu PJ, Yu J, Zeng ZR, Leung WK, Lin HL, Tang BD, Bai HAC and Sung JJY: Chemoprevention of gastric cancer by celecoxib in rats. Gut 53: 195-200, 2004.